ArticleFrontiers in cardiovascular medicine2022

Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China.

Haiqiang Sang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.